MapLight Therapeutics stock crashes on Phase II schizophrenia data GlobalData predicts the schizophrenia market across the seven major markets will be worth $17bn in 2031. Credit: MGARCIA_CREATIVE / Shutterstock.com · Clinical Trials Arena · MGARCIA_CREAT... See more
MapLight Therapeutics’ stock crashed by more than 70% after the release of data from its Phase II schizophrenia trial, despite the study meeting its primary endpoint. In the Phase II ZEPHYR trial (NCT07038876), ML-007C-MA, an oral M1/M4 muscarinic agonist... See more
ViiV Healthcare’s two-drug regimen as good as Biktarvy, study finds Abigail Beaney Updated Tue, July 28, 2026 at 10:54 AM UTC 3 min read Add Yahoo as a preferred source to see more of our stories on Google. ViiV's HIV two-drug regimen was first approved i... See more
ViiV Healthcare’s two-drug regimen for HIV treatment is as effective as Gilead’s Biktarvy in treatment-naïve patients, as per findings from a Phase IIIb trial. In the VOGUE study (NCT05979311), Dovato (dolutegravir/lamivudine (DTG/3TC)) demonstrated non-i... See more
Artificial intelligence (AI) was a hot topic on the agenda at the American Society of Clinical Oncology (ASCO) meeting 2026, with its benefits in unstructured data continuing to bear fruit. Experts highlighted a rise in the number of AI-related abstracts ... See more
